China Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

China Breast Cancer Therapeutics Market Analysis

$ 3999

With rising incidences of breast cancer and new technological advancements in breast cancer therapeutics, the China breast cancer therapeutics market is projected to expand from $1.46 Bn in 2022 with a CAGR of 14.4% for the year 2022-2030 to $4.29 Bn in 2030. The China breast cancer market is segmented by therapy, cancer type, and by distribution channel. Shenzhen Main Luck Pharmaceuticals Inc., Bristol-Myers Squibb Co., Eli Lilly, and Co. are some of the key players in the market.

ID: IN10CNPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: China

Buy Now

China Breast Cancer Therapeutics Market Executive Analysis

The China breast cancer therapeutics market size is at around $1.46 Bn in 2022 and is projected to reach $4.29 Bn in 2030, exhibiting a CAGR of 14.4% during the forecast period. The National Bureau of Statistics of China has estimated that healthcare spending in China reached 6.9% of GDP in 2020 and is projected to increase to almost 7.5% of GDP by 2022. The Chinese government has invested significantly in reforming its healthcare system, which includes increasing expenditures and strengthening insurance coverage. Furthermore, the government has been funding the construction of new hospitals and clinics as well as the education of new medical personnel.

With more than 16 Mn new cases and 12 Mn fatalities from the disease every year, cancer is becoming a greater health burden in China. Breast cancer is currently the most prevalent cancer in Chinese women, and it accounts for 96% of all breast cancer deaths worldwide and 12.2% of all newly diagnosed cases of breast cancer. Along with typical therapies like radiation and chemotherapies, targeted therapies and hormone therapies are common forms of treatment for breast cancer in China. Some newer treatments, such as immunotherapy, are also being studied in clinical trials in China. Additionally, traditional Chinese medicine is sometimes used in conjunction with Western medicine to manage symptoms and side effects of breast cancer treatment.

China Breast Cancer Therapeutics Market

Market Dynamics

Market Growth Drivers

Major market drivers in China include the rising incidence of breast cancer and technological advancements. The breast cancer therapeutics market is anticipated to expand as a result of the Chinese government's investments in healthcare and cancer research.

Market Restraints

Lack of access to advanced treatments and the high cost of treatments in China are some of the major barriers to market growth. Limited healthcare infrastructure and reimbursement policies may also impede the growth of the breast cancer therapeutics market in China.

Competitive Landscape

Key Players

Wyeth China Inc. (CHN)
Shenzhen Main Luck Pharmaceuticals Inc. (CHN)
Bristol-Myers Squibb Co.
Eli Lilly and Co.
Halozyme, Inc.
Merck & Co., Inc.

Healthcare Policies and Regulatory Landscape.

The basic medical insurance policy in China's national healthcare system covers treatment for breast cancer. For those diagnosed with breast cancer, this program will pay for their surgery, radiation treatment, and chemotherapy. Targeted therapy and immunotherapy, however, may only be partially covered by the basic medical insurance policy because they are regarded as expensive treatments. Additionally, several cities have local pilot programs that provide coverage for novel breast cancer therapies like CAR-T therapy. The reimbursements offered in China are fully reimbursable, partially reimbursable, and non-reimbursable. They are primarily applicable to the SHANDONG region. Patients may be required to pay out-of-pocket for specific treatments or services that are not covered by insurance because of regional differences in coverage rules and reimbursement rates for breast cancer treatment.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.